Abbott: 3 Key Takeaways for Long-Term Investors

Abbott (ABT) plans to spin off its nutrition business into an independent public company, a structural shift that sharpens the company's focus on higher-margin medical technologies and diagnostics.

The move arrives alongside solid operating momentum. ABT reported 7% year-over-year comparable sales growth in Q3 2026. Cancer diagnostics sales climbed 14%, driven by Cologuard and new blood-based colorectal cancer screening tests.

Electrophysiology offers another growth lever. Pulsed field ablation technology is accelerating growth in that segment, and the source frames it as positioning ABT for growth beyond its historical rates.

Interpretation: the spinoff strips a lower-growth, lower-margin unit from the parent, which could leave a purer medtech and diagnostics profile for investors to value. The 14% diagnostics growth against 7% company-wide comparable growth shows where the mix is heading. Whether the market rewards that mix shift depends on execution, and the source offers no timeline or valuation detail for the separation.

Neither JNJ nor ISRG figures in the source, so any read-through to those names is speculative.